1. Valent P., Akin C., Hartmann K., et al. Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. Cancer Res. 2017; 77(6): 1261-1270. DOI: 10.1158/0008-5472.CAN-16-2234
2. Sperr W.R., Escribano L., Jordan J.-H. et al. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leukemia Research. 2001; 25(7): 529-536. DOI: 10.1016/s0145-2126(01)00041-8.
3. Valent P., Sillaber C., Bettelheim P. The growth and differentiation of mast cells. Prog Growth Factor Res. 1991; 3(1): 27-41.
4. Sperr W.R., Jordan J.H., Fiegl M. et al. Serum Tryptase Levels in Patients with Mastocytosis: Correlation with Mast Cell Burden and Implication for Defining the Category of Disease. International Archives of Allergy and Immunology. 2002; 128(2): 136-141. DOI:10.1159/000059404
5. M. Miettinen, J. Lasota. c-KIT (CD117): A Review on Expression in Normal and Neoplastic Tissues, and Mutations and Their Clinicopathologic Correlation. Applied Immunohistochemistry & Molecular Morphology. 2005; 13(3): 205-220. DOI: 10.1097/01.pai.0000173054.83414.22.
6. Kristensen T., Vestergaard H., Moller M. B. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn. 2011; 13(2): 180-8. DOI: 10.1016/j.jmoldx.2010.10.004.
7. Cardet J. C., Akin C., Lee M. J. Mastocytosis: update on pharmacotherapy and future directions. Expert Opin Pharmacother. 2013.; 14(15): 2033-45. DOI: 10.1517/14656566.2013.824424.
8. Metcalfe D. D. Mast cells and mastocytosis. Blood. 2008; 112 (4): 946-56. DOI:org/10.1182/blood-2007-11-078097
9. Sotlar K., Escribano L., Landt O., et al. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol. 2003; 162 (3): 737-46.
10. Jawhar M., Schwaab J., Schnittger S., et al. Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis. Leukemia. 2016; 30(1): 136-43. DOI: 10.1038/leu.2015.284.
11. Puri N., Roche P. A. Mast cells possess distinct secretory granule subsets whose exocytosis is regulated by different SNARE isoforms. Proc Natl Acad Sci U S A. 2008; 105(7): 2580-5. DOI.org/10.1073/pnas.0707854105
12. Cohen S. S., Skovbo S., Vestergaard H., et al. Epidemiology of systemic mastocytosis in Denmark. Br J Haematol. 2014; 166(4): 521-8. DOI: 10.1111/bjh.12916
13. Valent P., Akin C., Sperr W. R., et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol. 2003. 122(5): 695-717. DOI:10.1046/j.1365-2141.2003.04575.x
14. Briley LD, Phillips CM. Cutaneous mastocytosis: a review focusing on the pediatric population. Clin Pediatr (Phila) 2008; 47(8): 757–61.
15. Лебедева Т. Ю., Федерякина О. Б., Дубенский В. В., Катунина О. Р. Мастоцитоз у детей. Тверской медицинский журнал. 2014; 1: 48-61.
16. Lange M, Niedoszytko M, Renke J et al. Clinical aspects of paediatric mastocytosis: a review of 101 cases. J Eur Acad Dermatol Venereol 2013; 27: 97–102. DOI: 10.1111/j.1468-3083.2011.04365.x.
17. Brockow K. Epidemiology, prognosis, and risk factors in mastocytosis. Immunol Allergy Clin North Am. 2014; 34: 283–95. DOI: 10.1016/j.iac.2014.01.003
18. Koga H., Kokubo T, Akaishi M et al. Neonatal onset diffuse cutaneous mastocytosis: a case report and review of the literature. Pediatr Dermatol 2011; 28: 542–6. DOI: 10.1111/j.1525-1470.2010.01212.x
19. Horny HP, Metcalfe DD, Akin C, et al. Mastocytosis. In: Swerdlow SH et al., eds. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. Lyon, France: International Agency for Research and Cancer (IARC); 2017:62-69.
20. Castells M, Metcalfe DD, Escribano L. Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations. Am J Clin Dermatol 2011; 12: 259–70. DOI: 10.2165/11588890-000000000-00000.
21. Meni C, Bruneau J, Gorgin-Lavialle S, et al. Paediatric mastocytosis: a systematic review of 1747 cases. Br J Dermatol. 2015;172:642;
22. Caplan RM. The natural course of urticaria pigmentosa. Arch Dermatol. 1963;87:146;
23. Heide R, Tank B, Oranje AP. Mastocytosis in childhood. Pediatr Dermatol. 2002;19:375;
24. Marrouche N, Grattan C. TMEP or not TMEP: that is the question. J Am Acad Dermatol 2014; 70: 581–2. DOI: 10.1016/j.jaad.2013.09.006.
25. Vannorsdall EJ, Collins JA, Chen QC, et al. Symptomatic response to imatinib mesylate in cutaneous mastocytosis associated with chronic myelomonocytic leukemia. Curr Oncol. 2013;20:349–53. DOI: 10.3747/co.20.1301.
26. Berezowska S, Flaig MJ, Ruëff F et al. Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis. Mod Pathol. 2014; 27(1): 19–29. DOI: 10.1038/modpathol.2013.117.
27. Захарцева Л. М, Шатрова К. М., Крячок И. А., и др. Системный мастоцитоз с преимущественным поражением костной и лимфатической системы (обзор литературы и случай из практики). Онкология; 2015. 17(4): 236-242.
28. Alvarez-Twose I., Morgado J.M., Sánchez-Muñoz L., er al. Current state of biology and diagnosis of clonal mast cell diseases in adults. International Journal of Laboratory Hematology. 2012; 34(5): 445-460 DOI: 10.1111/j.1751-553X.2012.01427.x.
29. Синельникова Н. А., Калинина Н. М., Савенкова Н. Д. Хроническая крапивница в детском возрасте. Формы хронической крапивницы у детей. Дифференциальная диагностика (часть II). Медицинская иммунология. 2013; 15(4): 313-324.